- OpGen ( NASDAQ: OPGN ) said on Tuesday it had signed a collaboration agreement with Swiss pharma firm BioVersys AG for the use of its Unyvero platform in BioVersys’ Phase II clinical trial of drug candidate BV100.
- BV100 is an injectable formulation of rifabutin to treat serious infections caused by Carbapenem Resistant Acinetobacter baumannii (CRAB) in patients with ventilator-associated bacterial pneumonia (VABP), hospital-acquired bacterial pneumonia (HABP) and bloodstream infections (BSI).
- In the trial, Hospitals will use Unyvero HPN for hospitalized pneumonia patients as a rapid diagnostic test.
- ( OPGN ) has risen ~2% before the bell.
For further details see:
OpGen signs agreement with Bioversys for Unyvero platform for rapid diagnostics